Clinical trials: Invasive Ductal Breast Cancer
Artificial Intelligence (AI) in Diagnosis
Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component
The goal of this clinical trial is to see if an artificial intelligence (AI)-assisted method helps doctors more accurately detect invasive breast cancer in people with a specific type of tumor called "extensive intraductal…
- Trial name
- INSIGHT-EIC (NCT07060599)
- Testing
- INvasion Screening with Intelligent Guidance for Histopathology Triage (INSIGHT) Workflow
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Genetics of Women With Lobular Carcinoma in Situ of the Breast
RATIONALE: Gathering information about genetic changes in patients with lobular carcinoma in situ of the breast may help doctors learn more about the disease and find better methods of treatment.
- Trial name
- NCT00536718
- Testing
- gene expression analysis, molecular diagnostic method, polymorphism analysis
- Where
- 9 sites in United Kingdom
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Research Network
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182793
- Testing
- trastuzumab, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Outcome of Breast Cancer
Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer
A prospective observational longitudinal study of 464 patients was performed between 2010 and 2015. Patients with invasive ductal carcinoma (IDC) and ductal carcinoma in situ associated to invasive ductal carcinoma (DCIS +IDC)…
- Trial name
- NCT03669952
- Testing
- None intervention
- Volunteers
- 464 people
- Sponsor
- Omphis Foundation
Breast Cancer
Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Radiation therapy may kill any tumor cells remaining after surgery. PURPOSE: Phase I/II trial to study the effectiveness of brachytherapy in treating women who have stage I or stage II breast cancer.
- Trial name
- NCT00002873
- Testing
- brachytherapy
- Where
- 232 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Ductal Carcinoma In Situ, Invasive Breast Cancer
The Prone Breast Radiation Therapy Trial
Participants undergoing radiation after breast conserving surgery for an early breast cancer (either Ductal Carcinoma In Situ (DCIS), or Early Stage Invasive breast cancer), and are at increased risk of developing a skin reaction…
- Trial name
- NCT01815476
- Testing
- Radiation Therapy Positioning Intervention
- Where
- 2 sites in Canada
- Volunteers
- 378 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre
Breast Cancer
Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002967
- Testing
- cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate
- Where
- 108 sites in United States, Canada
- Sponsor
- NSABP Foundation Inc
Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma
Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer
This pilot clinical trial studies magnetic resonance thermal image guided laser interstitial thermal therapy in treating patients with breast cancer.
- Conditions
- Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT01791998
- Testing
- magnetic resonance thermal imaging, laser interstitial thermal therapy
- Where
- United States
- Sponsor
- University of Chicago
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
This pilot clinical trial studies biomarkers in tissue samples from patients with newly diagnosed breast cancer treated with zoledronic acid (ZA).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer
- Trial name
- NCT01409811
- Testing
- zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Lobular Carcinoma
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
This study is being done in order to better understand the biology of an abnormal lesion found in breast tissue called "lobular carcinoma in situ" (LCIS). We are interested in studying LCIS.
- Conditions
- Breast Cancer, Lobular Carcinoma, Invasive Breast Cancer
- Trial name
- NCT00581750
- Testing
- Tissue specimen
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
CD133 Expression in Mammary Invasive Ductal Carcinoma
Background and Aim: Breast carcinoma is the most common type of cancer and the most common cause of cancer-related mortality among women worldwide.
- Trial name
- NCT04873154
- Where
- 2 sites in Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
DCIS, LCIS
Molecular Analysis of the Sloane Project
The Sloane Project is a UK wide prospective audit of screen detected non-invasive and atypical breast hyperplasias named after John Sloane an eminent pathologist interested in the field.
- Conditions
- DCIS, LCIS, Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia
- Trial name
- NCT05868252
- Where
- United Kingdom
- Volunteers
- 1,500 people
- Sponsor
- King's College London